In Australia, Admedus’s Board of Directors appointed Wayne Paterson, who has been serving as acting CEO since May 2016, to be their permanent CEO for the next three years. We recently reported on Ademedus’s expansion into Saudi Arabia and their recent growth, which Admedus’s Board Chairman, John Seaberg credits to Paterson’s restructuring and leadership. Seaberg told Proactive Investors, “As we saw with his ‘Code Red’ restructure, Wayne is a strong leader who has the ability, energy, savvy and networks that Admedus needs to accelerate the momentum we’ve already been able to achieve during just a few months on his watch.”
Paterson has extensive background in the pharmaceutical industry and had senior roles at Merck. Admedus is becoming increasingly known for its CardioCel biomaterial product which is used for heart valve repair surgeries.